PharmaTwoB was founded by a group of highly experienced professionals from the Israeli pharmaceutical industry, with strong track record in drug delivery, chemistry, finance and strategic planning. The company’s management and staff are highly skilled scientists with many years of experience in research and development of drugs, pharmaceutical development and clinical trials.

Clinical Advisors

C Warren Olanow, MD, FRCPC, FRCP (hon) - Chief Executive Officer

C. Warren Olanow M.D. has been Chief Executive Officer of CLINTREX® since its founding in 2008. He is the Henry P. and Georgette Goldschmidt Professor and Chairman Emeritus of the Department of Neurology, and Professor in the Department of Neuroscience at the Mount Sinai School of Medicine in New York City. He received his medical degree from the University of Toronto, and performed his neurology training at the New York Neurological Institute at Columbia University. He is a Past President of the Movement Disorder Society, Past President of the International Society of Motor Disturbances, Past Treasurer of the American Neurological Association, and past Editor-in Chief of the journal Movement Disorders. He was a founding member and served on the initial Executive Committee of the Parkinson Study Group. He has led multiple pivotal clinical trials including the Pergolide study, ADAGIO study, STRIDE-PD, Deep Brain Stimulation (DBS) for tremor, DBS for PD, Fetal nigral transplantation, gene delivery of neurturin, and the recently approved trial of levodopa/carbididopa intestinal gel (Duopa®) treatment. He has served on dozens of Scientific Advisory Committees for pharmaceutical and biotech companies, is a member of the Executive Committee of the Scientific Advisory Board of the Michael J Fox Foundation, and serves on the board of directors of the National Space Board Research Institute. He is an honorary professor at University College London (Royal Free Hospital), an honorary member of the French Neurological Society, an honorary fellow of the Royal College of Physicians in the United Kingdom (FRCP), and the recipient of the 2013 movement disorder research award from the American Academy of Neurology. He has published more than 375 peerreviewed articles and was named the most cited researcher in Parkinson’s disease in the United States over the past quarter century. He has lectured on Parkinson’s disease and other neurodegenerative disorders at universities and conferences throughout the world.

Karl Kieburtz, MD, MPH - President of CLINTREX

Karl Kieburtz has been the President of CLINTREX® since its inception in 2008. He is the Robert J Joynt Professor in the Department of Neurology, Professor in the Department of Public Health Science and Environmental Medicine, Director of the Clinical & Translational Science Institute, and Senior Associate Dean for Clinical Research at the University of Rochester. He attended medical school and performed a Neurology Residency at the University of Rochester, and obtained an MPH degree from the same institution. He previously served as Director of the Center of Human Experimental Therapeutics (CHET), and Director of the Clinical Trial Coordination Center (CTCC) at the University of Rochester. He is director of the clinical coordinating center for the Parkinson’s Progression Markers Initiative (PPMI) program sponsored by the Michael J Fox Foundation, and is a Scientific Advisor to the Alzheimer Disease Cooperative Study (ADCS). Dr. Kieburtz served as the Chair of the FDA Peripheral and Central Nervous System Advisory Committee. He was the past Chair of the Parkinson Study Group Executive Committee, and a past member of the Huntington Study Group Executive Committee. He served as Vice-President of the American Neurological Association, was a member of the International Executive Committee of the Movement Disorder Society, and was associate editor of the Neurology and Movement Disorder Journals. He has been PI for more than 50 multi-center NIH, industry, and Foundation sponsored clinical trials including the large NIH-sponsored multi-center NET-PD studies.

We at PharmaTwoB are
striving to make your
life better by developing
innovative, products
based on previously
approved drugs.